Purpose:To compare the safety and efficacy of cataract surgery using nasal clear corneal incision (CCI) versus superior or temporal CCIs in Korean patients. Methods: A retrospective comparative study was conducted. Patients underwent cataract surgery using CCI performed by 3 surgeons between January 2012 and December 2013.The patients were divided into the following 3 groups based on CCI direction: nasal CCIs (group I), superior CCIs (Group II), and temporal CCIs (Group III). To assess usability, surgically induced astigmatism (SIA), best-corrected visual acuity (BCVA), intraocular pressure (IOP), keratometry reading, and refractive errors at baseline and 1 month after surgery were compared. Operation times were compared between groups. To assess safety, intraoperative complications and wound stability were compared. Results: A total of 1,374 eyes (Group I, 283 eyes; Group II, 587 eyes; Group III, 504 eyes) were included in the present study. The SIA was not significantly different among the 3 groups. The postoperative mean BCVA, IOP, keratometry reading and spherical equivalent as well as the mean operation times were not significantly different between the 3 groups (14.04 ± 3.79 vs. 13.80 ± 3.27 vs. 13.80 ± 3.70; p = 0.473). The rate of intraocular complications and incidence of corneal wound suture were not significantly different between the 3 groups (1.7% vs. 3.2% vs. 2.3%; p = 0.378). Conclusions:The safety and efficacy of cataract surgery using nasal CCI were not significantly different compared with the use of temporal or superior CCI. Our results showed that cataract surgery using nasal CCI can be performed safely and conveniently in Korean patients.

Purpose:To compare the clinical efficacy of intravitreal ranibizumab and aflibercept in treatment-naïve patients with polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively analyzed the medical records of 82 eyes with treatment-naïve PCV who were treated with ranibizumab or aflibercept and followed for at least six months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) as measured by optical coherence tomography (OCT), and polyp size in indocyanine green angiography (ICGA) were used for evaluation. The primary endpoint was change at 12 months relative to baseline with respect to BCVA and CFT. Secondary endpoints were anatomical changes in OCT and ICGA findings from baseline. Results: Data from 46 eyes were considered for the primary endpoint. Twenty-five and 21 eyes received ranibizumab and aflibercept, respectively. Statistically significant improvements in BCVA and CFT compared with baseline were noted in both groups. Of 82 eyes assessed for secondary endpoints, 52 and 30 received ranibizumab and aflibercept, respectively. The subretinal fluid , pigment epithelial detachment , and subfoveal thickness decreased significantly throughout the follow-up in each group. Polyp regression was found in 37.5% and 32.4% of the ranibizumab-and aflibercept-treated groups, respectively. However, there was no significant difference in the treatment results between the drugs. Conclusions: In a comparison of the clinical efficacy of intravitreal ranibizumab and that of aflibercept in patients with PCV, the treatment groups showed similar clinical results in terms of functional and anatomical outcomes after 12 months.